Clinical Research Directory
Browse clinical research sites, groups, and studies.
Adenosine Pre-Medication in Primary Percutaneous Coronary Intervention
Sponsor: National Institute of Cardiovascular Diseases, Pakistan
Summary
Primary objective of the study is to evaluate the impact of adenosine pre-medication on incidence of slow flow/no-reflow after primary percutaneous coronary intervention.
Official title: Adenosine Pre-Medication in Primary Percutaneous Coronary Intervention: A Randomized Control Trial
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
1148
Start Date
2025-06-01
Completion Date
2026-12-31
Last Updated
2026-04-22
Healthy Volunteers
No
Conditions
Interventions
Adenosine pre-medication
Patients will receive intracoronary adenosine before primary PCI in addition to standard pharmacological therapy: Dose: 2 mg for left coronary artery, 1 mg for right coronary artery Dilution: 20 mL normal saline Route: Intracoronary (proximal via guide catheter or distal via delivery device) Timing: Administered immediately prior to PCI Purpose: To evaluate whether adenosine pre-medication reduces the incidence of slow flow/no-reflow and improves myocardial perfusion outcomes (TIMI flow grade and Myocardial Blush Grade).
Standard care
Patients will receive standard pharmacological management during primary PCI without adenosine pre-medication. Purpose: Serves as the control to assess the effect of adenosine on slow flow/no-reflow and myocardial perfusion.
Locations (2)
National Institute of Cardiovascular Diseases
Karachi, Sindh, Pakistan
National Institute of Cardiovascular Diseases
Karachi, Sindh, Pakistan